- Email: [email protected]
Cefotaxime in the treatment of staphylococcal infections
experiewe.
lane Avenole, New Deans, LA, USA. Received 1 March 19?%;revised and accepted 30 March 1995. DIAGN tvIICR0BIBL INFECT DE 1995;22995-201 0 1995 Elsevier $Ticience Inc. 655 Avenue of the Americas, New York, NY 10010
0732
SSWI0732~8a
50 -5
ai
In vitro
Activity
ofCefotaxime
Qxa&n-Susceptible
and Other
Stapbylococci~
SfuphyZ0coccus aureus No. of
Cefotaxime
Ceftriaxone Ceftazidime Cephalathid Cefazolin
No. of
Stkns
MIC,
% Susceptible
Strains
18,372 12,680 14,702
G2-8 62-4 8-32
94-100 94-99 89-94
3149 6681 6681
Gh5.3 8-16 16 to a32
77-95 77-94 62-85
85-100
4062
8
%-92
IO,%1 0.2-a
“Thesedataare compiledfromreferences(13) publishedfrom 1979-1995: Neu et al., NW; Jones and Thorn&arty, 1982, Mnekowitzet al., 1983; Weinstein, 1988;Turnidge et al., 1989; C 199%lnoue et al., P99C2Thornsberry et al., 1993;Barraddl and Bysun, 1994;Murray 1990;c arshall et al., 1995;and Baron and Jones, 1995. et al., 1
the involvement of staphylococci, especially S. aureus, in certain clinical ~dications for cefotaxime is rare; for example S. uureus common. As a result, little with sta~bylococci for certain in
Sf~p~yZ~c~cc~smreus is the cause of 2%-10% of all
of selected in vitro studies published 5 (Table 1) indicate that remains relatively stable with MU’&.,valtherapeutic range of concentrations (G3 or this agent with regard to oxacillinsusceptible S. wureus. Cefotaxime shows comparable activity to ceftriaxone and some “first-generation” s, but greater activity than ceftazivalues for cefotaxime ranged from ~2 nd in most studies 95% or more of S. RUBS strains were susceptible to cefotaxime. Against oxacillin-susceptible S. taxime was more active above or c~~t~z~dirne.
cornm~~~~-acquires pneu titularly devastating ip1t with postinfluenza pneu ses of S. aureus
corpus strains.
bolatior~ of S. ~~reus from the blood often indicates
endocarditis or arises as a consequence of
htrave-
Skin and skin structure infections can present clinically with a wide variety of signs and may be
resent as a seconda
ections who were
cureor
cliticd
~rove~en~ota~
ms
s
S
s. Qureus s. f4uwus S
lW193 ll/ll 52I56
49152
)
S
5l5 S. aureus S. ~~~~is
S. iaureus S. Qur~~s Total
56
51 5 15/15 II
-
1
15/x5
.O%)
favorable response to ce er et al. (1982) and Jacobs et a
nick Effic~y of Ccfotaxime in Caused by ~~ap~ylocQcci
ent
LeFrockand Cart (1982)
s. ~~~~~ Total
19i20 63/67 (94.0%)
‘801~ andjointinfections. weomy&is.
3/3 19120 59162(95.2%)
Jacobs(1992)
a
stup~ylcBccus
Bacteremiakpsis
36139
QW%??AS stQ?d@?LWCUS
719
epidertddis
I
S. aweus S. eptimidis S. aureus S. ~i~~idis S. aureus S. ~~~~i~is S. ~~re~5 S. ~~i~~~~i~is S. aureus S. coleus
Total
27QLBs s/5 62l II 4l4 W 931102 2l2 111 2Ql20
S. aureus
overview of ce
ence of cefotaxime in infections caused by grampositive pathogens. I@ction 13(Suppl l):S112-$114. Cherubm CE, L,eFro& ) Cefotaxime in the treatment of meningitis. on (Suppl l):!%%-S72. Chin N-X, Neu NM, Neu HC (1990) Activity of cephdosporins against coagdase-negative staphylococci. Diqn Micro&l lnfkct Dis P367-69. Fujii R (1985) Experience with cefotaxime in infections caused by gram-positive pathogens, especiauy St~p~ys nureus. ~~~~tio~Id(Supp1 I):S%Sl3.
Inoue M, Okamoto R, Obubs T, Inoue
The use of cefQta~me in the treatitive pneumonias. hfection 13(S~~~I
aan versus mtravenous cefotaxime therapy for serious skin and skin structure infections. Am ] Med ~7(Supp~ Gomis , Herranz A, Aparicio P, FiIIoy JL, Pastor J (1990) Cefotikne in the treatment of chronic osteomyelitis caused by gram-negative bacilIi. J Antimicmb Chemtl;er 4(Suppl A):W2.
Karakusis PH, Trenhohne GM, Levin S (1 the use of cefotaxime in the treatment
s:
s
Microbid Infect Wis 19:PlLP20.
lane Avenole, New Deans, LA, USA. Received 1 March 19?%;revised and accepted 30 March 1995. DIAGN tvIICR0BIBL INFECT DE 1995;22995-201 0 1995 Elsevier $Ticience Inc. 655 Avenue of the Americas, New York, NY 10010
0732
SSWI0732~8a
50 -5
ai
In vitro
Activity
ofCefotaxime
Qxa&n-Susceptible
and Other
Stapbylococci~
SfuphyZ0coccus aureus No. of
Cefotaxime
Ceftriaxone Ceftazidime Cephalathid Cefazolin
No. of
Stkns
MIC,
% Susceptible
Strains
18,372 12,680 14,702
G2-8 62-4 8-32
94-100 94-99 89-94
3149 6681 6681
Gh5.3 8-16 16 to a32
77-95 77-94 62-85
85-100
4062
8
%-92
IO,%1 0.2-a
“Thesedataare compiledfromreferences(13) publishedfrom 1979-1995: Neu et al., NW; Jones and Thorn&arty, 1982, Mnekowitzet al., 1983; Weinstein, 1988;Turnidge et al., 1989; C 199%lnoue et al., P99C2Thornsberry et al., 1993;Barraddl and Bysun, 1994;Murray 1990;c arshall et al., 1995;and Baron and Jones, 1995. et al., 1
the involvement of staphylococci, especially S. aureus, in certain clinical ~dications for cefotaxime is rare; for example S. uureus common. As a result, little with sta~bylococci for certain in
Sf~p~yZ~c~cc~smreus is the cause of 2%-10% of all
of selected in vitro studies published 5 (Table 1) indicate that remains relatively stable with MU’&.,valtherapeutic range of concentrations (G3 or this agent with regard to oxacillinsusceptible S. wureus. Cefotaxime shows comparable activity to ceftriaxone and some “first-generation” s, but greater activity than ceftazivalues for cefotaxime ranged from ~2 nd in most studies 95% or more of S. RUBS strains were susceptible to cefotaxime. Against oxacillin-susceptible S. taxime was more active above or c~~t~z~dirne.
cornm~~~~-acquires pneu titularly devastating ip1t with postinfluenza pneu ses of S. aureus
corpus strains.
bolatior~ of S. ~~reus from the blood often indicates
endocarditis or arises as a consequence of
htrave-
Skin and skin structure infections can present clinically with a wide variety of signs and may be
resent as a seconda
ections who were
cureor
cliticd
~rove~en~ota~
ms
s
S
s. Qureus s. f4uwus S
lW193 ll/ll 52I56
49152
)
S
5l5 S. aureus S. ~~~~is
S. iaureus S. Qur~~s Total
56
51 5 15/15 II
-
1
15/x5
.O%)
favorable response to ce er et al. (1982) and Jacobs et a
nick Effic~y of Ccfotaxime in Caused by ~~ap~ylocQcci
ent
LeFrockand Cart (1982)
s. ~~~~~ Total
19i20 63/67 (94.0%)
‘801~ andjointinfections. weomy&is.
3/3 19120 59162(95.2%)
Jacobs(1992)
a
stup~ylcBccus
Bacteremiakpsis
36139
QW%??AS stQ?d@?LWCUS
719
epidertddis
I
S. aweus S. eptimidis S. aureus S. ~i~~idis S. aureus S. ~~~~i~is S. ~~re~5 S. ~~i~~~~i~is S. aureus S. coleus
Total
27QLBs s/5 62l II 4l4 W 931102 2l2 111 2Ql20
S. aureus
overview of ce
ence of cefotaxime in infections caused by grampositive pathogens. I@ction 13(Suppl l):S112-$114. Cherubm CE, L,eFro& ) Cefotaxime in the treatment of meningitis. on (Suppl l):!%%-S72. Chin N-X, Neu NM, Neu HC (1990) Activity of cephdosporins against coagdase-negative staphylococci. Diqn Micro&l lnfkct Dis P367-69. Fujii R (1985) Experience with cefotaxime in infections caused by gram-positive pathogens, especiauy St~p~ys nureus. ~~~~tio~Id(Supp1 I):S%Sl3.
Inoue M, Okamoto R, Obubs T, Inoue
The use of cefQta~me in the treatitive pneumonias. hfection 13(S~~~I
aan versus mtravenous cefotaxime therapy for serious skin and skin structure infections. Am ] Med ~7(Supp~ Gomis , Herranz A, Aparicio P, FiIIoy JL, Pastor J (1990) Cefotikne in the treatment of chronic osteomyelitis caused by gram-negative bacilIi. J Antimicmb Chemtl;er 4(Suppl A):W2.
Karakusis PH, Trenhohne GM, Levin S (1 the use of cefotaxime in the treatment
s:
s
Microbid Infect Wis 19:PlLP20.